Analysts give Incyte a 60% chance of getting epacadostat approved in skin and lung cancer indications and an estimated $100,000 per patient price tag, 3 billion yearly sales by 2025. Adam F. recently compared Oncosec to Incyte. 10 billion dollars worth of Incyte market cap is based on this unapproved drug. Speculation of a takeover by Gilead has pumped up their share price upwards of $140 a share this year.
I am only posting this as a comparison to show just how undervalued Oncosec is compared to Incyte in market cap. Oncosec treatment would likely be cheaper and undercut Incyte's $100,000 analyst price estimate. Oncosec may have a nice competitive edge over other treatments regarding safety too.
If Oncosec can get just a sliver of the partnership interest that Incyte has gotten......boom! We will be at $20 or more a share.
The clearing out of the warrants says they are preparing for a move up to the big leagues soon.
Market Data 
Markets 
AI
